A new exploratory study published in Frontiers in Oral Health by researchers at Texas A&M Health Science Center and their collaborators now offers a detailed molecular portrait of what happens inside the mouths of these patients after treatment. The team followed 16 patients with newly diagnosed head and neck cancer, collecting chewing-stimulated whole saliva before radiotherapy and again at one and three months afterward. Using a custom magnetic Luminex assay capable of quantifying 25 cytokines simultaneously, the investigators tracked a broad panel of chemokines, interleukins, growth factors, and other immune signaling molecules. The design allowed each patient to serve as their own control, a powerful approach that reduces the confounding introduced by individual variation in baseline oral health, tumor biology, and immune status.

The first and most clinically immediate finding confirmed what oncologists and dentists have long observed at the chairside: chewing-stimulated saliva flow rates fell significantly in most patients. Twelve of the 16 patients had decreased flow by one month after radiotherapy, and seven of the eight patients who remained in the study at three months showed the same decline. Critically, the drop persisted without significant recovery between the one-month and three-month measurements, underscoring the chronic nature of radiation-induced salivary hypofunction. Because less saliva is produced, the oral environment loses its principal buffering, lubricating, and antimicrobial defense system, setting the stage for radiation-induced dental caries, mucosal discomfort, and secondary infections.

The cytokine analysis, however, is where the study makes its most distinctive contribution. One month after radiotherapy, saliva concentrations of 10 of the 25 measured cytokines had risen significantly compared with baseline. This roster included the chemokines CCL2 and CXCL1, the growth factors M-CSF, HGF, and GDF15, and the pro-inflammatory mediators IL-1α, IL-1β, IL-4, IL-6, and TNFα. By three months, eight of these ten molecules were still elevated, and two additional pro-inflammatory cytokines, GM-CSF and IL-18, had joined the list. Meanwhile, the anti-inflammatory and regulatory cytokines IL-10 and IL-27 showed no significant change, meaning the post-radiotherapy salivary environment tilted decisively toward inflammation rather than resolution.

Interpreting these concentrations required a technical subtlety that matters for anyone working in salivary diagnostics. Because flow rate itself decreased after radiotherapy, a rise in the absolute concentration of a cytokine per milliliter could partly reflect the shrinking volume of saliva rather than increased production by the glands. To account for this, the researchers calculated flow rate-adjusted levels, expressed in picograms per minute, which better approximate the actual cytokine output and immune activity within the salivary tissue. When the data were normalized this way, the picture narrowed: only seven cytokines showed significant increases in secretion rate, and just two of them, CCL2 and GDF15, remained elevated at both one and three months. IL-1β and IL-6 rose only at the one-month mark, while GM-CSF, IL-1α, and IL-18 became elevated only at three months, hinting at a temporal shift from acute inflammatory signaling toward a more chronic phase of glandular stress.

The identities of these persistent molecules are biologically telling. CCL2 and CX3CL1 are chemokines that recruit leukocytes into damaged tissue. IL-1α, IL-1β, IL-4, IL-6, IL-18, and TNFα drive apoptosis, cellular senescence, and inflammatory cascades. M-CSF and GM-CSF govern the differentiation and activation of myeloid cells, including the macrophages that preclinical work has implicated as central players in radiation injury and repair of salivary glands. GDF15 has been linked to the senescence of epithelial and endothelial cells after irradiation, while HGF, which also rose in this cohort, is known to counteract apoptosis and senescence in radiated tissues. The overall profile therefore suggests that irradiated glands are locked in a state of prolonged inflammatory and stress signaling, a molecular echo of the damage that may ultimately drive fibrosis, immune dysfunction, and permanent loss of secretion.

To test whether the human findings reflect events occurring within the glands themselves rather than elsewhere in the body, the team turned to mouse models. Using previously collected RNA samples from mouse submandibular glands at four and thirty days after radiation, they performed quantitative reverse transcription polymerase chain reaction for the cytokines that had changed most clearly in patient saliva. The results were strikingly parallel: mRNA levels of Ccl2, Gdf15, IL1a, IL1b, and IL6 were significantly elevated at both time points after irradiation. Even more encouraging, extracellular vesicles derived from induced pluripotent stem cell-derived mesenchymal stem cells, a regenerative therapy that the group has previously shown to preserve salivary function in mice, suppressed the chronic elevation of these cytokine transcripts by day thirty, with the exception of IL1a. Genes for GM-CSF and IL18, by contrast, were not significantly affected by radiation or by the therapy, mirroring the more variable behavior of those molecules in patients.

This convergence between human saliva and mouse gland tissue carries real translational weight. If salivary cytokine profiles genuinely report on the inflammatory state of the irradiated glands, they could serve as non-invasive biomarkers for predicting which patients will develop severe dry mouth, for stratifying patients toward macrophage-targeting and anti-inflammatory therapies now being explored in preclinical models, and for monitoring whether such interventions are working. Prior studies have already shown that patients with oral cancers carry higher salivary levels of IL-1β, IL-6, IL-8, IL-10, and TNFα than healthy controls, and that recurrence-free survivors treated with radiation, but not surgery alone, show further persistent increases. The new data extend and quantify that signal across a much broader cytokine panel and at matched time points within the same patients.

The authors are careful to frame the work as proof of concept rather than definitive clinical guidance. The cohort was small, limited by funding constraints, and attrition reduced the sample from eighteen patients at baseline to sixteen at one month and only eight at three months. Cytokine concentrations varied widely between individuals and followed lognormal rather than normal distributions, and the researchers did not adjust for multiple comparisons, so the findings are exploratory and descriptive, with P-values to be interpreted cautiously. Validation in larger, multi-center cohorts with longer follow-up will be essential before salivary cytokine profiling can enter routine oncology or dental practice.

Even so, the study opens a concrete path toward a long-standing clinical problem. Radiation-induced dry mouth has resisted decades of symptomatic management because the molecular mechanisms of glandular injury in actual patients have remained poorly characterized. By showing that a panel of pro-inflammatory cytokines rises measurably and persistently in saliva after treatment, that the most robust changes survive correction for reduced flow, and that these same signals appear in animal glands where regenerative therapies can reverse them, the Texas A&M-led team has identified both a potential diagnostic window and a set of therapeutic targets. For the hundreds of thousands of head and neck cancer survivors living with xerostomia, a simple saliva test that reveals the state of their glands, and treatments that quiet the inflammatory storm the beams have unleashed, would represent a transformative advance in survivorship care.

Subject of Research: Salivary cytokine changes in head and neck cancer patients after radiotherapy and their relevance to radiation-induced dry mouth

Article Title: Changes of salivary cytokines in head and neck cancer patients following radiotherapy

Article References: Zhao, Q., Jaiswal, J., Yu, V., Chang, E., Zhang, Y., Mendoza, L., Noureldin, A. A. K., Wang, X., & Liu, F. (2026). Changes of salivary cytokines in head and neck cancer patients following radiotherapy. Frontiers in Oral Health, 7, Article 1969672. https://doi.org/10.3389/froh.2026.1969672

Image Credits: AI Generated

DOI: 10.3389/froh.2026.1969672

Keywords: head and neck cancer, radiotherapy, salivary glands, cytokines, xerostomia, saliva biomarkers, CCL2, GDF15, inflammation, macrophages, extracellular vesicles, radiation-induced dry mouth

Duchenne muscular dystrophy is an X-linked childhood disease caused by loss of dystrophin, the protein that stabilizes muscle fibers during contraction. Delandistrogene moxeparvovec attempts to compensate by using an AAVrh74 viral vector to ferry a miniaturized micro-dystrophin gene into heart and skeletal muscle. Five FDA-approved gene therapies now rely on intravenous recombinant adeno-associated virus (rAAV), but the enormous doses needed to transduce enough tissue have produced serious adverse events and even deaths in clinical practice, making a detailed understanding of the body’s systemic reaction to these infusions a pressing safety concern.

The new study, led by researchers at the University of Florida Myology Institute, examined plasma and urine samples banked from four young boys in the NCT03375164 trial, all between four and eight years old. These participants received 2.0 × 10¹⁴ vector genomes per kilogram of rAAVrh74 carrying the micro-dystrophin transgene, and all four experienced effective muscle expression, multiyear functional improvement, and no serious adverse events. That makes them, in the researchers’ words, among the best representatives of a successful micro-dystrophin gene therapy, and therefore an ideal case study of what a favorable response looks like at the molecular level.

Using digital PCR to count viral genomes and immunoblotting to detect capsid proteins, the team found extraordinarily high levels of circulating vector one day after infusion, exceeding 10¹² vector genomes per milliliter of plasma. By day 7, plasma titers had dropped more than a thousandfold, to roughly 10⁹ vector genomes per milliliter or below. Urinary shedding was minimal and highly variable; two participants showed undetectable levels at every time point, while the highest value observed was 6 × 10⁶ vector genomes per milliliter in a single day 1 urine sample.

Critically, the circulating virus was not just inert debris. DNase pretreatment experiments showed that most of the detected genomes were protected inside intact capsids, and when day 1 plasma was added to cultured AC16 human cardiomyocytes, the particles successfully transduced the cells, proving that at least some of the vector remained biologically active a full day after infusion. This finding also addressed a recent concern in the field: laboratory studies have suggested AAV particles can spontaneously eject their genomes at body temperature, but the new data indicate genome ejection is not a prominent feature of systemic AAVrh74 therapy in humans.

The proteomic analysis told a more dramatic story. Using the SomaScan platform, which measures more than 5,000 circulating proteins with DNA-aptamer reagents, the researchers found 287 protein targets significantly altered across the treatment time course, and 99 targets changing at a stricter statistical threshold. Pathway analysis revealed that these changes were overwhelmingly concentrated in immune and infection-related programs: iron regulation, collagen biosynthesis, interleukin-6 signaling, complement and coagulation cascades, and ferroptosis all ranked among the most enriched pathways, even though none of the boys developed serious clinical complications.

The temporal pattern suggested an acute, self-limiting innate antiviral response. Interferon-stimulated genes such as MX1, IFIT3, IFI16, and TLR5 spiked sharply at day 7, coinciding with vector clearance, and largely returned to baseline by day 14. Macrophage markers like HMOX1, LST1, and MARCKSL1, along with neutrophil proteins including MPO, LCP1, and EZR, followed the same trajectory. Complement activation markers C3d, C1QTNF1, and C1S also peaked at day 7, while C1q components dropped at day 14, consistent with consumption during cascade activation. Notably, IL1R1 rose later, peaking at days 60 to 90 during the glucocorticoid taper, suggesting a rebound of interleukin-1 signaling as steroid suppression wore off rather than a direct effect of the virus.

Muscle biomarkers painted a nuanced picture of treatment effect. Sustained declines in TNNI3, a cardiac troponin, and MYL6B, a slow-fiber myosin light chain, hint at protection of heart and slow skeletal muscle. But a striking day 1 spike in titin, TTN, suggested transient muscle damage at the moment of infusion, and the classic damage markers fast troponin, cardiac troponin T, and creatine kinase showed no significant change at all. A newly proposed marker, the ubiquitin-conjugating enzyme UBE2S, declined steadily across the study and may reflect reduced muscle turnover as the transgene takes hold. Meanwhile, organ injury markers HAVCR1, FBP1, and IGFBP7 all peaked at days 60 to 90, and GDF15, a tissue stress signal, rose from day 7 and stayed elevated for at least three months, possibly explaining the vomiting that all participants experienced, since GDF15 is now linked to nausea in pregnancy and chemotherapy.

To test whether these immune signatures translate across species, the team injected dystrophic D2.mdx mice with a matching systemic rAAV dose and examined their livers a week later. Genes central to viral sensing and interferon signaling, including Ifit3, Ifnb, and Mavs, were significantly elevated, confirming that the antiviral response seen in human plasma also occurs in dystrophic liver tissue. The mouse work offers a tractable model for dissecting mechanisms and testing interventions, though the top human hit, MX1, only trended upward in mice, likely because inbred mouse strains carry nonfunctional Mx1 mutations.

The findings establish that robust immune activation is a natural and probably universal consequence of high-dose rAAV therapy, not merely a warning sign of impending toxicity. The key clinical question is what separates the transient, self-limiting response observed here from the sustained immune pathology seen in patients who develop hepatotoxicity, thrombotic microangiopathy, or fatal outcomes. By providing a detailed molecular reference point from a best-case scenario, the study gives clinicians a benchmark for monitoring future patients and points toward interventions, including complement control and anti-GDF15 strategies, that could make systemic gene therapy safer for the children who need it.

Subject of Research: Systemic immune and viral dynamics following intravenous rAAV micro-dystrophin gene therapy in boys with Duchenne muscular dystrophy

Article Title: Systemic responses to intravenous rAAV administration in boys with Duchenne muscular dystrophy

Article References: Harris, B. E., Seldin, B. M., Towne, S. C., Hobson, O. R., Zerpa, E., Prima, V., Sweeney, H. L., & Hammers, D. W. (2026). Systemic responses to intravenous rAAV administration in boys with Duchenne muscular dystrophy. Frontiers in Molecular Medicine, 6, Article 1953867. https://doi.org/10.3389/fmmed.2026.1953867

Image Credits: AI Generated

DOI: 10.3389/fmmed.2026.1953867

Keywords: rAAV gene therapy, Duchenne muscular dystrophy, micro-dystrophin, delandistrogene moxeparvovec, AAVrh74, SomaScan proteomics, interferon response, complement activation, digital PCR, vector dynamics, GDF15, immune response biomarkers

The hormone in question is growth differentiation factor 15, commonly abbreviated as GDF15. It belongs to a large family of signaling proteins that coordinate development, metabolism, and stress responses throughout the body. GDF15 has attracted considerable attention in recent years for its roles in appetite regulation and nausea of pregnancy, but its function during fetal development has remained poorly understood. The new study, led by Xiao Peng Liu, Xiao Zhang, and colleagues, set out to determine whether this circulating protein might be more than a bystander in pregnancy, and whether the placenta itself might be an important source of the hormone that reaches the developing fetus.

The researchers began by measuring GDF15 levels in two different animal models of fetal growth restriction, one in mice and one in pigs. In both species, they found that GDF15 concentrations were significantly reduced in the placenta and in the fetal circulation. Crucially, the degree of reduction tracked closely with fetal weight: the lower the GDF15 level, the smaller the fetus. This correlation alone did not prove causation, but it provided a clear starting hypothesis. If GDF15 were merely a symptom of a struggling pregnancy, its levels would fall alongside everything else. If it were a driver of growth, removing it should be enough to restrict fetal development on its own.

To distinguish between these possibilities, the team engineered mice in which the Gdf15 gene was deleted specifically in the placenta while leaving the rest of the embryo genetically intact. The result was striking. Fetuses carrying placentas that could no longer produce GDF15 developed fetal growth restriction, even though their own tissues were fully capable of making the hormone. This experiment demonstrated that placental GDF15 is not redundant with GDF15 produced elsewhere in the fetus. The placenta, an organ long viewed primarily as a supplier of oxygen, nutrients, and waste exchange, appears to function as an endocrine gland whose hormonal output directly programs fetal growth.

The next question was where the placental hormone goes and what it does once it arrives. By tracing the contribution of placental GDF15 to the fetal bloodstream, the researchers found that the placenta is a major contributor to the pool of GDF15 circulating in the fetus. The protein crosses into the fetal compartment and accumulates in the fetal liver, the metabolic powerhouse of the developing animal and the source of insulin-like growth factors that drive tissue expansion throughout the body. There, GDF15 engaged a well-known intracellular signaling pathway called STAT3, a transcription factor that becomes active when it is chemically modified by phosphorylation and then moves to the nucleus to switch genes on or off.

The target gene at the end of this pathway proved to be IGF2, or insulin-like growth factor 2, one of the most potent fetal growth promoters known to biology. IGF2 is famous among developmental biologists for its imprinting, meaning it is expressed from only one parental copy of the gene, and for its dramatic effects: mice engineered to lack IGF2 are born at roughly sixty percent of normal size. The new findings place placental GDF15 upstream of this master growth factor, activating hepatic STAT3 signaling, which in turn stimulates IGF2 production during pregnancy. When placental GDF15 was missing, the researchers measured reduced phosphorylation of STAT3 and reduced IGF2 levels in fetal livers, providing a coherent mechanistic chain from placenta to fetal liver to whole-body growth.

To confirm that STAT3 was genuinely required for this effect rather than merely correlated with it, the team turned to primary fetal hepatocytes, liver cells isolated directly from mouse fetuses and grown in culture. When these cells were exposed to GDF15, they responded by ramping up IGF2 production. But when the researchers inhibited STAT3 signaling in the same cells, the GDF15-induced increase in IGF2 was blocked. This loss-of-function experiment in a controlled cellular system strengthens the causal interpretation considerably. It shows that the hormone acts through STAT3, not around it, and that the STAT3 to IGF2 axis is the specific conduit through which placental GDF15 exerts its growth-promoting influence on the fetal liver.

Perhaps the most clinically exciting part of the study is what happened when the researchers tried to reverse the damage. Rather than delivering the GDF15 protein itself, which can be difficult to dose and target, they used a technology that has surged to prominence in recent years: lipid nanoparticles, the same delivery vehicles that made mRNA vaccines possible. The team encapsulated messenger RNA encoding Gdf15 into lipid nanoparticles engineered to target the placenta and administered them to pregnant animals whose placentas were deficient in the hormone. The treatment raised GDF15 levels in the placenta and fetal circulation, and the fetuses grew better, showing effective alleviation of fetal growth restriction. Importantly, the therapy also restored the downstream molecular signals, with treated FGR fetuses showing recovered hepatic phosphorylated STAT3 and IGF2 levels, confirming that the intervention worked through the same pathway the researchers had mapped.

The implications of this work extend in several directions at once. For basic developmental biology, the study establishes what the authors call a placenta-fetal liver metabolic axis, a hormonal communication line in which the placenta secretes GDF15 into the fetal circulation to activate hepatic STAT3 signaling and thereby stimulate IGF2-driven growth. This reframes the placenta as an active endocrine participant in fetal development rather than a passive interface. For obstetric medicine, the findings suggest that low placental GDF15 could serve as a biomarker for identifying pregnancies at risk of fetal growth restriction, potentially allowing earlier and more targeted surveillance. And for therapy, the demonstration that placenta-targeted mRNA delivered by lipid nanoparticles can rescue fetal growth in animal models opens a concrete path toward a treatment, something the field has lacked for decades.

Considerable work remains before any of this reaches the clinic. The study was conducted in mice and pigs, and the human placenta, while sharing many features with these models, differs in important ways that will need to be addressed in follow-up research. The safety of manipulating a growth signaling pathway during pregnancy, a period when even subtle perturbations can have lasting consequences, will demand rigorous evaluation, particularly given IGF2’s association with uncontrolled growth when dysregulated. Dosing, timing, and the long-term metabolic health of treated offspring are all open questions. Nevertheless, the identification of a specific, druggable placental hormone with a defined downstream pathway marks a genuine advance in understanding why some fetuses fail to grow, and it offers the first credible blueprint for intervening in the condition at its mechanistic root rather than simply watching and waiting.

Subject of Research: The role of placental GDF15 in regulating fetal growth through the hepatic STAT3-IGF2 pathway and its therapeutic potential for fetal growth restriction

Article Title: Deficiency of placental GDF15 causes fetal growth restriction by inhibiting fetal hepatic STAT3-IGF2 axis

Article References: Liu, X. P., Zhang, X., Cai, C. X., Qin, M. M., Leng, X. K., Chen, J. H., Han, Y. F., Xiao, J. Y., Huang, J. H., & Wu, J. W. (2026). Deficiency of placental GDF15 causes fetal growth restriction by inhibiting fetal hepatic STAT3-IGF2 axis. PLOS Biology, 24(10), e3004061. https://doi.org/10.1371/journal.pbio.3004061

Image Credits: AI Generated

DOI: 10.1371/journal.pbio.3004061

Keywords: GDF15, fetal growth restriction, placenta, STAT3, IGF2, fetal liver, lipid nanoparticles, mRNA therapy, PLOS Biology, pregnancy, endocrine signaling, developmental biology

Allostatic load is a concept borrowed from stress physiology, first articulated in the 1990s to describe the cumulative physiological cost of repeated adaptation to adversity. Rather than measuring stress as a feeling, it aggregates objective markers drawn from routine clinical data: blood pressure, body mass index, waist-to-hip ratio, cholesterol fractions, blood glucose, inflammatory markers such as C-reactive protein, and indicators of organ function across the cardiovascular, metabolic, immune, and endocrine systems. When many of these markers drift into abnormal territory at the same time, the body is effectively operating in a state of sustained emergency. The researchers behind the new study treated this composite score as a single, quantifiable index of physiological dysregulation, and asked a deceptively simple question: does it predict lung cancer independently of smoking, age, and the other usual suspects?

The answer, drawn from a prospective analysis of 336,945 UK Biobank participants, appears to be yes. Each one-unit increase in the allostatic load score was associated with a 7.3 percent increase in lung cancer risk, with a hazard ratio of 1.073 and a 95 percent confidence interval of 1.053 to 1.094. When participants were grouped into categories, those classified as low allostatic load had a 28.4 percent higher risk than the normal group, while the high group carried a 62.9 percent higher risk, with a hazard ratio of 1.629. Crucially, the team examined histological subtypes separately and found the signal was not uniform. Small-cell lung cancer showed the strongest association, while lung adenocarcinoma and squamous cell carcinoma also displayed significant links. That pattern is intriguing because small-cell tumors are tightly tied to neuroendocrine biology and heavy tobacco exposure, raising questions about how systemic physiological stress might intersect with those pathways.

Genetics, of course, is the other half of the risk equation. The investigators constructed a polygenic risk score — a weighted sum of many common genetic variants each contributing a small increment of susceptibility — to capture each participant’s inherited predisposition to lung cancer. They then asked whether allostatic load and genetic risk acted independently, or whether one amplified the other. The result was striking in its clarity: the two factors combined multiplicatively in the data but showed no evidence of statistical interaction. In other words, they stack rather than synergize. Participants who sat in the high-allostatic-load group and simultaneously carried high genetic risk faced a 136.9 percent increase in lung cancer risk — a hazard ratio of 2.369, with a confidence interval of 1.565 to 3.583 — roughly two and a half times the risk of comparable individuals without either burden.

That finding has immediate practical implications for screening. Low-dose computed tomography, or LDCT, is the only screening modality proven to reduce lung cancer mortality, but eligibility criteria — typically built around age, smoking intensity, and smoking duration — miss a meaningful fraction of people who ultimately develop the disease. The researchers tested whether adding allostatic load to the existing eligibility framework improved risk discrimination, and it did. The composite stress measure provided incremental stratification beyond established LDCT screening criteria, suggesting that a panel of cheap, routinely collected clinical markers could help flag high-risk individuals whom current guidelines overlook. Because allostatic load is calculated from data already gathered in ordinary checkups, the barrier to testing this idea in clinical settings is far lower than for most novel biomarkers.

But the study did not stop at epidemiology. One of its most ambitious components was an attempt to peer inside the black box connecting cumulative physiological dysregulation to carcinogenesis, using plasma proteomics — the large-scale measurement of circulating proteins. Integrating proteomic data with machine learning, pathway enrichment, and mediation analyses, the team identified 111 proteins whose circulating levels were associated with allostatic load. Within that set, 34 proteins showed potential mediation signal, meaning their statistical behavior was consistent with the idea that they might lie on the causal path between physiological dysregulation and lung cancer. Among the leading candidates were hepatocyte growth factor (HGF), chemerin (RARRES2), and growth differentiation factor 15 (GDF15) — molecules with well-documented roles in inflammation, metabolism, cell growth, and stress signaling.

The identity of these candidate mediators is scientifically telling. HGF is a potent growth factor involved in tissue repair and cell migration, and it has been implicated in tumor invasion and metastatic behavior across multiple cancers. RARRES2, also known as chemerin, is an adipokine — a signaling molecule released by fat tissue — that links metabolic state to immune function, fitting neatly with the idea that metabolic dysregulation is a central pillar of allostatic load. GDF15 is one of the most consistently elevated proteins in contexts of tissue stress, inflammation, and aging, and elevated circulating GDF15 has been repeatedly associated with poor health outcomes and cancer presence. That all three emerged from an unbiased, data-driven screen lends biological plausibility to the epidemiological association, pointing toward inflammatory, metabolic, and growth-factor-related processes as the connective tissue between chronic stress physiology and lung carcinogenesis.

The authors are careful, appropriately, to frame the proteomic findings as exploratory. Mediation analysis in observational data can suggest pathways but cannot prove causation, and reverse causation — early, undetected tumors altering circulating protein levels — remains a consideration in any prospective cancer study. Still, the design has notable strengths. The cohort was large and prospective, meaning allostatic load was measured before cancer diagnosis, which reduces the likelihood that the disease drove the biomarker rather than the reverse. The study also adjusted for established confounders and examined subtype-specific outcomes, which is where some of the most interesting biology surfaced. The pronounced association with small-cell lung cancer, in particular, invites follow-up work on how chronic inflammatory and endocrine stress might influence neuroendocrine differentiation in the lung.

What makes the study resonate beyond lung cancer specialists is its conceptual reframing of risk. Lung cancer risk assessment has long been dominated by behavioral exposure — chiefly smoking — and inherited genetics. Allostatic load sits at the intersection of those factors and everything else that shapes physiological wear: occupational strain, socioeconomic adversity, sleep, diet, chronic disease, and the accumulated micro-stresses of daily life. A composite biomarker of this kind does not identify a single culprit; instead, it captures the integrated output of many upstream causes. That is both its strength and its limitation. It offers a powerful summary signal for risk stratification, but it does not by itself tell clinicians which intervention — stress reduction, metabolic management, blood pressure control — would most effectively lower a given patient’s risk.

The road from association to clinical practice runs through replication and, ultimately, intervention trials. Future studies will need to confirm these findings in independent cohorts with different demographic profiles, refine how allostatic load is scored, and test whether incorporating it into screening algorithms genuinely reduces lung cancer mortality rather than merely reshuffling risk categories. The proteomic mediators identified here — HGF, RARRES2, GDF15, and their 31 companions — now constitute a testable biological hypothesis, one that laboratory models and interventional studies can interrogate directly. If the findings hold, the implications are considerable: a measurable, modifiable, and routinely computable indicator of cumulative physiological burden could join age and smoking history in the calculus of who deserves a closer look for the world’s leading cause of cancer death. For now, the study stands as a compelling demonstration that the body’s long memory of stress, written in blood pressure, metabolism, and inflammation, may be legible in cancer risk as well.

Subject of Research: The association of allostatic load and genetic susceptibility with lung cancer risk and its proteomic mediators

Article Title: Allostatic load, genetic susceptibility, and lung cancer risk: Evidence from a prospective cohort and integrative proteomic analyses

Article References: Yang, F., Wang, W., Chen, F., Wang, Z., Wang, Y., Qi, T., He, Z., Liang, S., Bu, Q., Qiu, X., Jiaqing, D., Ren, S., Dai, J., & Wang, X. (2026). Allostatic load, genetic susceptibility, and lung cancer risk: Evidence from a prospective cohort and integrative proteomic analyses. PLOS Digital Health, 5(10), e0001766. https://doi.org/10.1371/journal.pdig.0001766

Image Credits: AI Generated

DOI: 10.1371/journal.pdig.0001766

Keywords: allostatic load, lung cancer, UK Biobank, polygenic risk score, proteomics, small-cell lung cancer, LDCT screening, chronic stress, GDF15, HGF, risk stratification, PLOS Digital Health

The endoplasmic reticulum, or ER, is the cellular organelle responsible for folding and quality-controlling newly synthesized proteins. When protein folding demand outstrips capacity, misfolded proteins accumulate in the ER lumen, triggering a coordinated adaptive program known as the unfolded protein response. This response is orchestrated by three principal sensors embedded in the ER membrane, one of which is PERK, or protein kinase RNA-like ER kinase. Upon activation, PERK phosphorylates the translation initiation factor eIF2α, which globally dampens protein synthesis to relieve the folding burden while selectively upregulating ATF-4, a transcription factor that reprograms cells toward amino acid metabolism, antioxidant defense, and autophagy. Because the PERK–ATF-4 arm of the unfolded protein response is intimately tied to nutrient sensing and metabolic adaptation, researchers have increasingly suspected it might be relevant to hyperemesis gravidarum, a condition defined in part by starvation-like physiology.

The research team, led by Bahriye Oznur Oguçbilek of Darende Hulusi Efendi State Hospital in Malatya, Turkey, together with colleagues from Konya City Hospital and Selçuk University, designed a prospective case-control study conducted between August and November 2024. They enrolled 85 pregnant women diagnosed with hyperemesis gravidarum within the first 16 weeks of gestation, alongside 85 healthy pregnant women serving as controls. Ethical approval came from the Karatay University Scientific Research Ethics Committee, and all participants provided written informed consent. The investigators measured circulating levels of PERK and ATF-4 in serum using enzyme-linked immunosorbent assays, then compared the two groups and explored how the markers related to clinical and laboratory characteristics, including urinary ketone status, a bedside indicator of the fasting and fat-metabolism state that often accompanies severe vomiting.

The headline result was a clear and statistically robust difference in ATF-4. Women with hyperemesis gravidarum had significantly lower serum ATF-4 concentrations than controls, with a median of 4.55 nanograms per milliliter in the patient group versus 6.16 nanograms per milliliter in healthy pregnant women, a difference that reached significance at p equals 0.002. Strikingly, PERK levels themselves did not differ between the groups, with medians of 3.73 and 3.29 nanograms per milliliter respectively and a p-value of 0.965. This dissociation is intriguing from a mechanistic standpoint. If the PERK–ATF-4 axis were simply activated as part of a classical stress response, one might expect coordinated changes in both proteins. The selective reduction of ATF-4 without a corresponding PERK shift hints that the integrated stress response in hyperemesis gravidarum may be modulated at a level downstream of PERK, or that circulating ATF-4 reflects contributions from tissues responding to nutritional stress in ways that do not track with PERK abundance in blood.

Correlation analysis added another layer of complexity. Across the hyperemesis group, the control group, and the overall study population, ATF-4 and PERK levels were strongly and positively correlated, with Spearman correlation coefficients of 0.837, 0.709, and 0.765 respectively, all highly significant. This tight coupling suggests that the two proteins are physiologically linked in pregnancy, consistent with their partnership in the canonical stress pathway, even though the disease state shifts the overall set point of ATF-4 downward. In other words, the relationship between the two markers is preserved, but the baseline against which that relationship plays out appears to be altered in women experiencing severe nausea and vomiting.

The researchers also asked whether ATF-4 levels differed according to urinary ketone positivity within the hyperemesis group, reasoning that ketosis marks the most metabolically stressed patients. The answer was no: ATF-4 concentrations did not vary significantly with ketone status, with a p-value of 0.282. This null result suggests that the ATF-4 signal is not simply a readout of acute starvation severity as captured by a single urine dipstick measurement. It may instead reflect a broader or more chronic adaptation to the hyperemetic state, or it may be influenced by factors such as hydration status, treatment, or individual variation in stress pathway regulation that a ketone test cannot capture.

To assess clinical utility, the team performed receiver operating characteristic analysis, asking whether serum ATF-4 could discriminate hyperemesis patients from healthy pregnant women. The answer was, at best, modestly. The area under the curve was 0.638, statistically significant at p equals 0.001, but corresponding to limited discriminatory power. At the chosen threshold, sensitivity was 45.9 percent, meaning more than half of true cases would be missed, while specificity reached 77.6 percent. In practical terms, ATF-4 alone is not ready to serve as a diagnostic biomarker for hyperemesis gravidarum. However, the statistically significant separation between groups indicates the marker carries real biological information, and the authors frame their findings as a foundation for further molecular and longitudinal investigation of the PERK–ATF-4 axis rather than as the basis for an immediate clinical test.

The study sits within a rapidly evolving research landscape. Hyperemesis gravidarum has historically been under-studied and sometimes dismissed as a psychological or trivial complaint, but the 2018 identification of associations between the placental and appetite genes GDF15 and IGFBP7 and the condition, followed by the landmark 2024 Nature study linking GDF15 to maternal risk of nausea and vomiting of pregnancy, has transformed the field. GDF15 is now understood to act as an endocrine signal of nutritional and cellular stress, acting on hindbrain circuits that suppress appetite and induce nausea. The new ATF-4 findings dovetail conceptually with this work: the integrated stress response is precisely the intracellular machinery through which cells sense amino acid deprivation and metabolic duress, and ATF-4 is the transcriptional executor of that response. A lowered circulating ATF-4 in hyperemesis patients may therefore represent another fingerprint of the same stress physiology that elevated GDF15 signals, though the direction of the change and the causal chain remain to be established.

Endoplasmic reticulum stress is also well documented in other pregnancy complications, lending plausibility to its involvement in hyperemesis. Increased ER stress has been reported in decidual tissue from pregnancies complicated by fetal growth restriction and preeclampsia, and ER stress signaling has been shown to mediate proinflammatory cytokine inhibition of trophoblast invasion. The PERK–ATF-4–CHOP pathway has been implicated in hypoxia-induced trophoblast apoptosis in preeclampsia, and the same research group has previously examined ER stress parameters in gestational diabetes mellitus. Placental ER stress is often described as a double-edged sword, with moderate activation supporting adaptation while excessive or prolonged activation contributes to pathology. Against this backdrop, the observation that hyperemesis gravidarum is associated with reduced rather than elevated circulating ATF-4 is a reminder that systemic markers may not mirror tissue-level stress responses, and that the placenta, liver, and other metabolically active organs may each contribute differently to the blood pool of these proteins.

The authors are careful about the limitations inherent in their design. As a cross-sectional case-control study, it demonstrates association rather than causation, and it cannot determine whether reduced ATF-4 precedes, accompanies, or results from hyperemesis gravidarum. ELISA measurements of circulating proteins capture only what reaches the bloodstream, not the intracellular activation state of the pathway in placental or hypothalamic tissue where the biology likely unfolds. The study period was confined to a few months in late 2024, and the cohort was drawn from Turkish hospital settings, raising questions about generalizability that only multi-center and longitudinal work can resolve. Still, the strong correlations, the significant group difference, and the explicit call for longitudinal follow-up give the field a concrete next step. If future studies confirm and extend these findings, the PERK–ATF-4 axis could become a mechanistic bridge connecting the hormonal triggers of hyperemesis gravidarum, such as GDF15, to the cellular stress physiology that produces its debilitating symptoms, and perhaps eventually to targeted interventions for the roughly one to three percent of pregnancies it complicates worldwide.

Subject of Research: Endoplasmic reticulum stress markers PERK and ATF-4 in hyperemesis gravidarum

Article Title: Investigation of Endoplasmic Reticulum Stress in Pregnant Women with Hyperemesis Gravidarum

Article References: Oguçbilek, B. O., Kuzu, K., Akat, F., Almaghrebi, E., Vatansev, H., & Sarıkaya, S. (2026). Investigation of Endoplasmic Reticulum Stress in Pregnant Women with Hyperemesis Gravidarum. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02228-y

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02228-y

Keywords: hyperemesis gravidarum, endoplasmic reticulum stress, ATF-4, PERK, unfolded protein response, pregnancy, GDF15, integrated stress response, ketosis, ELISA, placenta, Reproductive Sciences

The endoplasmic reticulum is far more than a passive protein factory. When misfolded proteins accumulate inside it, because of starvation, inflammation, oxidative damage, or hormonal upheaval, the organelle triggers a coordinated rescue program known as the unfolded protein response. Three sensor proteins embedded in the ER membrane police this quality-control checkpoint, and one of them, PERK, is the focus of the new work. When PERK detects trouble, it phosphorylates the translation initiation factor eIF2alpha, which globally damps protein synthesis to give the cell breathing room, while selectively upregulating activating transcription factor 4, or ATF-4. ATF-4 then reprograms the cell toward amino acid import, antioxidant defense, and autophagy. If the stress persists and the adaptive response fails, ATF-4 can instead push the cell toward apoptosis, which is why the PERK–ATF-4 axis sits at the crossroads between adaptation and damage in conditions ranging from diabetes to preeclampsia.

Pregnancy is itself a physiological stress test for this pathway. The placenta is a site of intense protein synthesis, low oxygen tension in early gestation, and brisk inflammatory signaling, and previous studies have documented heightened ER stress markers in decidual and placental tissue from pregnancies complicated by fetal growth restriction and preeclampsia. The same research group had previously examined ER stress parameters in gestational diabetes, finding measurable alterations in circulating stress markers. That body of work made a natural question irresistible: if the unfolded protein response is perturbed in other pregnancy complications, does it also leave a fingerprint in the blood of women with hyperemesis gravidarum, a condition whose biology remains stubbornly incomplete despite recent genetic breakthroughs linking it to the hunger hormone GDF15?

To find out, the team led by Bahriye Oznur Oguçbilek and Sevcan Sarıkaya designed a prospective case-control study conducted between August and November 2024. They enrolled 85 pregnant women diagnosed with hyperemesis gravidarum within the first 16 weeks of gestation, alongside 85 healthy pregnant controls matched for early pregnancy. The researchers measured circulating levels of PERK and ATF-4 in serum using enzyme-linked immunosorbent assays, then interrogated the data with group comparisons, Spearman correlation analyses, and receiver operating characteristic analysis to see whether either protein could serve as a diagnostic marker. Ethical approval came from the Karatay University Scientific Research Ethics Committee, and all participants provided written informed consent before enrollment.

The headline result was a significant reduction, not an elevation, of serum ATF-4 in the hyperemesis group. Women with the condition had a median ATF-4 concentration of 4.55 nanograms per milliliter, with an interquartile range spanning 0.82 to 42.86, compared with 6.16 nanograms per milliliter, ranging from 2.23 to 29.27, in healthy controls, a difference that reached statistical significance at p equal to 0.002. PERK, by contrast, was essentially indistinguishable between the two groups, with medians of 3.73 and 3.29 nanograms per milliliter and a p value of 0.965. That dissociation is biologically intriguing. If the upstream sensor is unchanged while its principal downstream transcriptional effector is depleted, it suggests that whatever is happening in these women is not a straightforward amplification of canonical ER stress signaling, but something more selective, perhaps involving post-translational regulation, altered clearance, or consumption of ATF-4 in tissues rather than a simple overactivation of the pathway.

Equally striking was the strength of the relationship between the two proteins. ATF-4 and PERK levels correlated strongly and positively in every analysis the team performed: the Spearman correlation coefficient was 0.837 within the hyperemesis group, 0.709 among controls, and 0.765 across the entire study population, all with p values below 0.001. In other words, the two molecules rise and fall together in the circulation of pregnant women regardless of disease status, reinforcing the idea that they travel as a coupled axis in vivo. But within the hyperemesis group, ATF-4 levels did not differ according to urinary ketone positivity, the standard bedside marker of starvation and fat metabolism that clinicians use to gauge severity, with a p value of 0.282. The circulating stress signature, in short, did not track the most obvious clinical indicator of nutritional deprivation.

Could ATF-4 serve as a diagnostic test? The receiver operating characteristic analysis suggests caution. The area under the curve was 0.638, statistically significant at p equal to 0.001 but well short of the discrimination clinicians would want in a standalone test. At the optimal cutoff, ATF-4 achieved a specificity of 77.6 percent, meaning it rarely mislabeled healthy pregnancies as diseased, but a sensitivity of only 45.9 percent, meaning it missed more than half of true cases. The authors are appropriately measured in their interpretation, describing the discriminatory performance as limited and framing the finding as a hypothesis-generating result rather than a clinical tool. The value of the study lies in what it reveals about mechanism, not in any immediate application at the bedside.

Placed in context, the findings add an unexpected twist to a rapidly evolving field. The dominant molecular story in hyperemesis research over the past several years has centered on GDF15, the placental and appetite-regulating hormone that acts on the brainstem to suppress feeding. Landmark genetic studies published in Nature and Nature Communications identified GDF15 and IGFBP7 as risk loci, and a 2024 Nature paper linked maternal GDF15 levels directly to nausea and vomiting risk, culminating in a multi-ancestry genome-wide association study of severe pregnancy sickness. Meanwhile, oxidative stress has been documented in hyperemesis patients, and systemic inflammation markers have been associated with the condition in recent case-control work. The new data suggest that the unfolded protein response, long implicated in placental pathology, deserves a seat at the same table, even if its circulating signature points downward rather than upward.

Why might ATF-4 be lower rather than higher? The authors themselves do not overclaim an explanation, and the honest answer is that the study cannot distinguish among several possibilities. Chronic starvation and ketosis can suppress integrated stress response signaling in some tissues; the adaptive phase of the response may have resolved by the time of sampling; or circulating levels may simply mirror what is consumed and bound in metabolically active tissues rather than what is produced. It is also worth remembering that ATF-4 is a transcription factor whose biology is governed by context: in the placenta, the same pathway that protects trophoblasts under mild stress can drive apoptosis under severe or prolonged stress, a duality that recent reviews have called the stress paradox of the unfolded protein response in pregnancy. A single serum measurement captures one frame of a dynamic process.

The study’s limitations are those of any cross-sectional case-control design: it captures a snapshot, cannot establish causality, and relies on peripheral blood rather than placental tissue, where the most consequential ER stress biology likely unfolds. The authors call explicitly for molecular and longitudinal investigation of the PERK–ATF-4 axis in hyperemesis gravidarum, and that is the right next step. Serial sampling through pregnancy, tissue-level studies of placental and hepatic stress signaling, and integration with the GDF15 and inflammatory axes could reveal whether the depressed ATF-4 signature is a cause, a consequence, or a bystander of the disease. For the roughly one to three percent of pregnancies affected by hyperemesis gravidarum, a condition the Windsor international consensus definition now recognizes as a distinct disorder with serious consequences for quality of life, any new molecular handle is welcome. This study does not yet change clinical practice, but it opens a genuinely novel window onto a condition that has, for too long, been understood mostly by what it is not.

Subject of Research: Endoplasmic reticulum stress markers in pregnant women with hyperemesis gravidarum

Article Title: Investigation of Endoplasmic Reticulum Stress in Pregnant Women with Hyperemesis Gravidarum

Article References: Oguçbilek, B. O., Kuzu, K., Akat, F., Almaghrebi, E., Vatansev, H., & Sarıkaya, S. (2026). Investigation of Endoplasmic Reticulum Stress in Pregnant Women with Hyperemesis Gravidarum. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02233-1

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02233-1

Keywords: hyperemesis gravidarum, endoplasmic reticulum stress, ATF-4, PERK, unfolded protein response, pregnancy, placenta, GDF15, case-control study, ELISA, morning sickness, Reproductive Sciences

The research team, led by investigators at the Aging Research Center of Karolinska Institutet and Stockholm University, set out with a specific and technically ambitious goal. Rather than examining a single disease endpoint, they wanted to identify the blood biomarkers most strongly associated with adherence to several well-established dietary patterns and to describe the pathophysiological domains those markers belong to. To do this, they drew on fifty-four blood biomarkers spanning four major domains: metabolic, inflammatory, vascular, and neurodegenerative. This breadth matters, because aging is not driven by any single pathway. It is the product of interacting processes, from glucose regulation and lipid transport to chronic low-grade inflammation and neural injury, and a diet’s biological fingerprint may be scattered across all of them.

Dietary intake in the study was assessed using validated food frequency questionnaires, the standard instrument for capturing what people eat over extended periods. The researchers then scored diet quality in three complementary ways. The first was adherence to the Alternative Mediterranean Diet, or AMED, a scoring system that rewards high consumption of vegetables, legumes, fruits, nuts, whole grains, fish, and monounsaturated fats, with moderate alcohol intake and limited red and processed meat. The second was the Alternative Healthy Eating Index, or AHEI, a broader index developed to capture foods and nutrients most strongly linked to lower chronic disease risk. The third was a reverse-transformed Empirical Dietary Inflammatory Index, or rEDII, which quantifies the inflammatory potential of the diet; higher rEDII scores in this transformation indicate a less pro-inflammatory, and therefore more favorable, dietary pattern.

On the statistical side, the team used quantile regression to examine cross-sectional associations between dietary adherence and standardized biomarker levels, adjusting for sociodemographic and lifestyle factors. Quantile regression is a technically deliberate choice: by modeling the median of each biomarker distribution rather than only the mean, the approach is less sensitive to extreme values and outliers, which are common in biological data from older populations. The researchers also corrected for multiple comparisons, a safeguard against the false positives that inevitably arise when dozens of biomarkers are tested simultaneously. Associations were expressed per one standard deviation increment in dietary adherence, allowing effects to be compared across different diets and biomarkers on a common scale.

The results were striking in their specificity. Higher adherence to the Mediterranean-style AMED pattern was directly associated with higher blood levels of folic acid, with a beta coefficient of 0.066, and inversely associated with glial fibrillary acidic protein, or GFAP, a marker of astrocyte activation that is increasingly studied as an indicator of neurodegenerative processes in the brain. The inverse association with GFAP, at a coefficient of -0.018, is particularly intriguing because it hints that a Mediterranean-style diet may be linked to a quieter profile of glial activity, the cellular inflammation within the brain that is thought to accompany cognitive aging. The AHEI showed a nearly identical association with folic acid, at 0.068, and was additionally inversely associated with growth differentiation factor 15, or GDF15, a circulating protein that rises with mitochondrial stress, inflammation, and biological aging more broadly.

The rEDII analysis told a complementary story. Higher adherence to the reverse-transformed inflammatory index, meaning a diet with lower inflammatory potential, was inversely associated with leptin, insulin, GDF15, alkaline phosphatase, tumor necrosis factor receptor superfamily member 1B, and leukocyte counts. The coefficients ranged from -0.047 for TNFRSF1B, a receptor shed during tumor necrosis factor signaling, to -0.094 for leptin, the hormone produced by fat tissue that regulates appetite and energy balance. In practical terms, older adults whose diets carried a lower inflammatory burden showed lower levels of hormones and signaling molecules tied to adiposity, insulin action, inflammatory cascades, and cellular stress responses. Leukocytes, the circulating immune cells that often rise with systemic inflammation, were also lower, at a coefficient of -0.058.

What makes this pattern biologically coherent is that the affected markers cluster into recognizable physiological narratives. Folic acid, elevated in those following Mediterranean-style and healthy eating patterns, is a B vitamin central to one-carbon metabolism, DNA synthesis, and the regulation of homocysteine, an amino acid implicated in vascular and neurological damage. GDF15, reduced among those eating less inflammatory diets, has emerged in geroscience as one of the most compelling blood-based indicators of biological age, rising steadily with tissue stress and chronic disease. TNFRSF1B and leukocytes sit squarely within the inflammaging framework, the slow-burning, low-grade inflammation that accumulates with age and is implicated in frailty, cardiovascular disease, and dementia. Alkaline phosphatase, meanwhile, is an enzyme associated with liver and bone metabolism that has been linked to metabolic and vascular risk in prior research.

The associations held up under scrutiny. The authors report that the findings remained consistent across multiple sensitivity analyses, a robustness check designed to test whether the results were artifacts of particular modeling choices or subgroups. The biomarker quantification itself was supported by the Affinity Proteomics-Stockholm unit at SciLifeLab, reflecting the kind of high-throughput proteomic infrastructure that has transformed what population-based aging studies can measure. Where earlier cohorts might have tracked a handful of clinical chemistry values, this study could interrogate dozens of proteins and metabolites simultaneously, then map the survivors of statistical correction back onto known pathophysiological domains.

It is worth being precise about what the study does and does not show. The design is cross-sectional, meaning diet and biomarkers were measured at the same point in time, so the analysis cannot establish that eating well causes favorable biomarker levels. Reverse causation remains possible: people with higher biological burden may eat differently, and underlying illness can reshape both appetite and blood chemistry. The effect sizes, while statistically robust after correction, are modest, as is typical for dietary epidemiology in free-living populations. Yet the consistency of the domain-specific signals, the use of validated dietary indices, and the population-based sampling all strengthen the case that the observed signature reflects genuine biology rather than statistical noise. The study was approved by the Regional Ethical Review Board in Stockholm, and all participants or their next of kin provided written informed consent.

For the field of geroscience, the work lands at a moment of growing interest in identifying modifiable levers over the biology of aging. Diet is among the most tractable of these levers, and the new findings suggest that its influence is legible in the blood, distributed across metabolic hormones, inflammatory receptors, and even markers of glial activity in the brain. If future longitudinal and interventional studies confirm that shifting dietary patterns moves these biomarkers in the directions observed here, the humble food frequency questionnaire may become an even more powerful clinical tool, one that connects everyday eating choices to the molecular machinery of healthier aging.

Subject of Research: Associations between dietary patterns and blood-based biomarkers of aging in older adults

Article Title: Biological signature of dietary patterns in older adults: findings from a population-based study

Article References: DaCosta, R. A., Gregorio, C., Calderón-Larrañaga, A., Ornago, A. M., Mrhar, A., Ortolá, R., Fredolini, C., Vetrano, D. L., & Carballo-Casla, A. (2026). Biological signature of dietary patterns in older adults: findings from a population-based study. BMC Medicine, 24(1), Article 520. https://doi.org/10.1186/s12916-026-05202-2

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05202-2

Keywords: nutrition, biomarkers, aging, Mediterranean diet, inflammation, GDF15, GFAP, folic acid, geroscience, diet quality, older adults, population-based study

The study, published in Aging Cell, is among the first to benchmark eleven proteomic organ clocks against molecular, imaging, cognitive and physical biomarkers within a single population. The organ clocks were originally developed by mapping thousands of plasma proteins to their tissues of origin and training mathematical models to predict chronological age for organs including the brain, heart, liver, kidney, immune system and arteries. When the researchers applied these clocks to the Scottish cohort, they found substantial heterogeneity: organs within the same person appeared to age at strikingly different rates, and the organ age gaps were only mildly correlated with one another, with a mean pairwise correlation of 0.32. Extreme ageing, defined as an organ age gap exceeding two standard deviations from the population mean, most commonly affected just a single organ rather than several at once.

Despite this biological richness, the organ clocks delivered only modest prognostic power. Each standard deviation of accelerated organ ageing corresponded to a 16 to 43 percent higher mortality hazard over the follow-up period. The strongest effects emerged for the liver, with a hazard ratio of 1.43, followed by the immune system at 1.42 and the heart at 1.38. The proteomic brain age gap, at a hazard ratio of 1.31, performed almost identically to a brain age gap derived from magnetic resonance imaging, which scored 1.30. These findings replicate the original organ clock study, which reported a 17 to 53 percent mortality increase per standard deviation in a separate American cohort, confirming that the approach generalises across populations.

Yet several other biomarkers left the organ clocks behind. The clear champion was GrimAge2, a second-generation epigenetic clock that estimates biological age from DNA methylation patterns in blood. A single standard deviation of GrimAge2 acceleration conferred a 62 percent higher mortality hazard, the largest effect of any biomarker tested. Close behind came structural brain measures: smaller total brain volume raised mortality risk by 52 percent per standard deviation, and smaller grey matter volume by 44 percent. Reduced lung function also proved formidable, with a one-second forced expiratory volume deficit carrying a 51 percent higher hazard, and poorer general cognitive function adding 46 percent. All of these surpassed every proteomic organ clock in effect size.

The researchers then asked which biomarkers carried independent information when all were considered simultaneously. In a multivariable Cox model including 21 ageing measures among the 460 participants with complete data, only four survived: total brain volume, white matter hyperintensity volume, general cognitive function and walking time. GrimAge2, despite its stellar univariable performance, lost significance, not because it lacks biological relevance but because much of its prognostic signal overlaps with correlated measures. Together, the four independent biomarkers explained roughly 19 percent of the variance in mortality risk, while all 21 biomarkers combined raised that figure only to 23 percent, suggesting diminishing returns from adding further measures.

The variance decomposition was equally revealing. Chronological age and sex accounted for just 2 percent of mortality risk, with lifestyle factors adding 4 percent. GrimAge2 contributed a further 6 percent, proteomic organ clocks 8 percent and physical function measures 9 percent. Brain-related measures, combining neuroimaging and cognition, accounted for around 16 percent, roughly double any other single domain. For the authors, this underscores that brain health, encompassing atrophy, cerebrovascular damage and cognitive capacity, is a particularly powerful window on survival in old age, likely because the brain regulates essential physiological functions and because atrophy captures neurodegenerative processes long before clinical diagnosis.

Beyond benchmarking clocks, the team mined the full plasma proteome for mortality signals. Using the SomaScan 11K platform, which quantifies nearly 10,000 protein targets from a small plasma sample, they identified 368 proteins significantly associated with all-cause mortality after adjustment for age and sex. The strongest positive associations belonged to GDF15, a stress- and inflammation-induced cytokine, with a hazard ratio of 1.56, followed by WFDC2 at 1.47 and TIMP1 at 1.45. Notably, GDF15 ranked as the second strongest mortality predictor overall, behind only GrimAge2, and three of the nine proteins whose DNA methylation surrogates are built into GrimAge2 appeared among the top twenty. On the protective side, higher circulating levels of neuropeptide S, BAGE3 and ABCC6 each corresponded to roughly 41 to 42 percent lower mortality risk per standard deviation.

Gene set enrichment analysis revealed a striking functional dichotomy among these proteins. Those whose higher levels predicted death were overwhelmingly enriched for immune processes, including antimicrobial humoral immune responses, chemokine and cytokine activity, and interleukin-4 and interleukin-13 signalling, painting a picture of inflammaging and immunosenescence, the chronic low-grade inflammation and immune decline that characterise ageing. Proteins associated with survival, by contrast, were enriched for genomic integrity: nucleosome assembly, regulation of the G2/M cell cycle transition, damaged DNA binding and ribosome biogenesis. Among the protective candidates were Sirtuin-2 and Caspase-2, both involved in DNA damage response and tumour suppression, with higher levels linked to 18 and 32 percent lower mortality risk respectively. An elastic net penalised regression across all 9,703 protein targets distilled the signal to just 37 proteins, with GDF15 carrying the largest positive coefficient and strong concordance with the univariate results.

The study has limitations the authors acknowledge. The cohort consists of relatively healthy, ethnically homogeneous Scots born in 1936, so validation in more diverse populations is needed. The analyses relied on single baseline measurements rather than longitudinal trajectories, examined all-cause rather than cause-specific mortality, and depended on one proteomics platform. The findings are observational and cannot establish causality. Still, the practical implications are considerable: simple, inexpensive measures such as walking speed, lung function and cognition rival or exceed costly molecular assays, while integrative biomarkers trained directly on mortality outcomes, like GrimAge2, currently offer the strongest single-molecule performance. Whether organ clocks add value for cause-specific mortality, such as distinguishing cardiac from neurological deaths, remains an open question.

What emerges is a clear message for the booming biological-ageing industry: no single number captures how fast someone is ageing. Organs age at their own pace, blood proteins tell one story, brain scans another, and the most informative forecast comes from combining complementary measures across modalities. As the world’s population over 60 doubles to a projected 2.1 billion by 2050, choosing the right combination of biomarkers could determine who benefits from early intervention, and the new results suggest that protecting the brain, preserving lung capacity and taming chronic inflammation may matter more than any single molecular clock.

Subject of Research: Multimodal ageing biomarkers and plasma proteomic signatures associated with all-cause mortality in older adults

Article Title: Multimodal Ageing Biomarkers and Plasma Proteomic Signatures Associated With All‐Cause Mortality

Article References: Pyrgioti, M., Eguiagaray, I. M., Redmond, P., Corley, J., Bastin, M. E., Hernández, M. V., Russ, T. C., Wardlaw, J. M., Hannon, E., Deary, I. J., Walker, K. A., Tucker‐Drob, E. M., Cox, S. R., Marioni, R. E., & Harris, S. E. (2026). Multimodal Ageing Biomarkers and Plasma Proteomic Signatures Associated With All‐Cause Mortality. Aging Cell, 25(10), Article e70747. https://doi.org/10.1111/acel.70747

Image Credits: AI Generated

DOI: 10.1111/acel.70747

Keywords: biological age, proteomic organ clocks, epigenetic clock, GrimAge2, all-cause mortality, plasma proteomics, GDF15, brain atrophy, cognitive function, lung function, immunosenescence, Lothian Birth Cohort 1936

MASLD has become one of the most common chronic liver conditions in the pediatric population, tracking closely with the global rise in childhood obesity. The disease involves the abnormal accumulation of fat within liver cells and, in a subset of patients, can progress to inflammation, fibrosis, and eventually cirrhosis. The challenge for clinicians is that the liver is remarkably silent in its early stages: children with accumulating hepatic fat typically feel well, and standard liver enzymes such as alanine aminotransferase can remain within normal limits even when fat infiltration is well established. The current diagnostic gold standard, liver biopsy, is rarely justified in children because of its invasiveness, cost, and sampling variability. Abdominal ultrasound is the usual screening tool, but it is operator-dependent and loses sensitivity when hepatic fat content is modest. This diagnostic gap is precisely what the Chinese team set out to address.

The researchers, led by Huanyu Wang and Zongming Yang of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, with corresponding authors Shimin Wu and Xiaoping Luo, conducted a cross-sectional study of children with obesity who presented to the hospital’s Department of Pediatrics between January 2023 and September 2024. The final analysis included 84 children, 53 boys and 31 girls, of whom 43—just over half—were diagnosed with MASLD based on abdominal ultrasound findings. Each child underwent anthropometric assessment, including body mass index z-score and waist-to-height ratio, alongside fasting metabolic panels. The team then quantified serum concentrations of five candidate biomarkers using enzyme-linked immunosorbent assays: cathepsin D, leptin, adiponectin, insulin-like growth factor 1, and growth differentiation factor 15.

These five molecules were not chosen at random. Each represents a distinct biological axis implicated in obesity-related liver disease. Cathepsin D is a lysosomal protease involved in intracellular protein degradation, and emerging evidence links it to lipid metabolism, insulin signaling, and hepatic inflammation. Leptin, the prototypical adipocyte-derived hormone, signals energy stores to the brain and participates in immune and fibrotic pathways in the liver. Adiponectin, another adipokine, is generally insulin-sensitizing and anti-inflammatory, and its levels tend to fall as metabolic health deteriorates. Insulin-like growth factor 1 mediates growth hormone action and is often altered in states of insulin resistance. Growth differentiation factor 15 is a stress-responsive cytokine of the transforming growth factor beta superfamily that rises in mitochondrial stress and systemic inflammation, and it has attracted attention as a broad marker of cardiometabolic risk.

The statistical approach was deliberately conservative. Rather than simply asking whether biomarker levels differed between children with and without MASLD, the investigators calculated odds ratios across tertiles of each biomarker after adjusting for established risk factors: age, sex, body mass index z-score, and waist-to-height ratio. This adjustment matters because any marker that merely reflects the degree of obesity adds little clinical value; the question was whether these proteins carry independent information about liver fat beyond what a clinician already knows from measuring a child’s size. The team also tested the shape of each association, allowing for nonlinear relationships rather than assuming a straight line.

The results were striking for cathepsin D. Children in the highest tertile of logarithmically transformed serum CTSD had roughly twelve-fold higher odds of MASLD compared with those in the lowest tertile, with an odds ratio of 12.63 and a 95 percent confidence interval spanning 2.57 to 84.62, and the association was linear across the distribution. Growth differentiation factor 15 also showed a robust positive association: children in the top tertile had nearly five times the odds of MASLD relative to the bottom tertile, with an odds ratio of 4.86 and a confidence interval of 1.14 to 23.57. Leptin told a more nuanced story. After full adjustment, its relationship with MASLD risk was inverse U-shaped, meaning risk peaked at intermediate leptin concentrations rather than rising monotonically. Children in the middle tertile had an odds ratio of 6.70 compared with the lowest tertile, and the test for nonlinearity yielded a p-value of 0.004. Adiponectin and insulin-like growth factor 1, by contrast, lost any significant independent association once conventional risk factors were accounted for.

Association alone, however, does not make a biomarker clinically useful. The researchers therefore asked whether adding each protein to a base prediction model containing age, sex, BMI z-score, and waist-to-height ratio actually improved diagnostic performance. They evaluated this with three complementary metrics: the area under the receiver operating characteristic curve, which measures overall discrimination; the continuous net reclassification improvement, which quantifies how many patients are moved into more accurate risk categories; and the integrated discrimination improvement, which assesses gains in predicted probabilities. Individually, each biomarker produced only marginal and statistically non-significant increases in the optimism-corrected AUC—for example, adding cathepsin D yielded a change in AUC of 0.047 with a p-value of 0.096.

Yet the reclassification analyses told a more encouraging story. Incorporating cathepsin D produced the most prominent improvement in risk stratification, with a continuous net reclassification improvement of 1.147 (95 percent confidence interval 0.152 to 1.657, p = 0.032) and an integrated discrimination improvement of 0.142 (95 percent confidence interval 0.014 to 0.339, p = 0.008). Leptin and insulin-like growth factor 1 also generated significant reclassification gains, with all p-values below 0.05. In practical terms, this means that even when a biomarker does not dramatically shift the average discrimination statistic, it can still meaningfully re-sort individual children into more appropriate risk categories—correctly elevating the estimated risk of those who truly have hepatic steatosis and lowering it for those who do not. For a condition in which the decision to pursue further imaging or specialist referral hinges on risk thresholds, such reclassification can translate directly into better-targeted care.

The biological plausibility of the three signal-bearing markers strengthens the case. Cathepsin D’s strong association fits with its emerging role as a mediator of lysosomal lipid handling and inflammatory signaling in hepatocytes. The leptin finding is particularly intriguing: the inverse U-shaped curve suggests that both relatively low and very high leptin concentrations carry different risk implications than intermediate levels, a pattern that could reflect receptor desensitization, leptin’s dual roles in appetite regulation and hepatic fibrogenesis, or confounding by adiposity distribution that the adjustment model only partially captures. Growth differentiation factor 15’s positive association aligns with its established behavior as a marker of cellular metabolic stress, which would be expected to rise as hepatic fat accumulation imposes mitochondrial and inflammatory burdens on the liver.

The authors are careful to frame these results as preliminary. With only 84 participants, the confidence intervals are wide, and the odds ratios—especially the double-digit estimate for cathepsin D—carry substantial statistical uncertainty. The cross-sectional design also means the study captures a single snapshot; it demonstrates association, not causation, and cannot establish whether elevated cathepsin D or GDF15 precede the development of steatosis or accompany it. The single-center recruitment from one pediatric obesity clinic further limits generalizability, and ultrasound-based diagnosis, while standard in clinical practice, is an imperfect reference. The team explicitly calls for validation in larger, multicenter cohorts before these markers enter clinical decision-making. Still, the study was approved by the Tongji Hospital Ethics Committee and supported by China’s National Key Research and Development Program and the Natural Science Foundation of Hubei Province, and it offers a concrete, testable hypothesis: that a small panel of serum proteins, measured alongside routine anthropometry, could sharpen the non-invasive detection of MASLD in children. If larger studies confirm the reclassification gains observed here, pediatricians may one day identify which of their young patients with obesity carry silent liver disease with a routine blood test—catching, at an early and potentially reversible stage, a condition that otherwise hides in plain sight for decades.

Subject of Research: Serum cardiometabolic biomarkers for diagnosing metabolic dysfunction-associated steatotic liver disease in children with obesity

Article Title: Association and diagnostic value of serum cardiometabolic biomarkers for metabolic-associated steatotic liver disease in children with obesity

Article References: Wang, H., Yang, Z., Wu, S., Weng, Y., Hou, L., Wu, W., & Luo, X. (2026). Association and diagnostic value of serum cardiometabolic biomarkers for metabolic-associated steatotic liver disease in children with obesity. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07697-3

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07697-3

Keywords: MASLD, pediatric obesity, cathepsin D, leptin, GDF15, biomarkers, fatty liver disease, non-invasive diagnosis, risk stratification, ELISA, children, hepatic steatosis

The starting point of the investigation was a computational strategy known as network toxicology, which treats a chemical, its protein targets, and human disease genes as nodes in an interconnected graph rather than as isolated entities. The researchers first assembled a comprehensive list of proteins that benzo[a]pyrene is known or predicted to interact with, drawing on established toxicogenomic databases and target-prediction tools. They then cross-referenced this list with genes associated with prostate cancer. The overlap was striking: 975 shared targets emerged, suggesting that BaP and prostate tumors converge on an unexpectedly large common molecular territory. When these 975 genes were mapped onto known biological pathways, the enrichment analysis pointed decisively toward the PI3K-Akt signaling axis, one of the most frequently hijacked growth and survival circuits in human malignancy, along with related networks governing cell proliferation, apoptosis resistance, and immune modulation.

Identifying 975 candidate genes is a useful beginning, but cancer biology demands sharper focus. To distill the signal, the team applied differential expression analysis to prostate cancer transcriptomic data and then deployed machine learning algorithms to select which of the differentially expressed genes best separated tumor from healthy tissue. Two complementary algorithms converged on four core genes: CAV1, TWIST1, PRKCA, and GDF15. Each of these has an established biography in cancer research. CAV1 encodes caveolin-1, a scaffolding protein of membrane caveolae with documented roles in prostate cancer progression and treatment resistance. TWIST1 is a transcription factor best known for orchestrating epithelial-to-mesenchymal transition, the cellular program that allows stationary epithelial cells to become invasive and migratory. PRKCA encodes protein kinase C alpha, described in recent work as a central node of tumorigenic transcriptional networks in the prostate. GDF15, or growth differentiation factor 15, is a stress-response cytokine whose levels correlate with aggressive and castration-resistant disease.

With the four core genes in hand, the investigators turned to transcriptomic verification. The expression pattern in prostate tumor datasets was coherent and directional: TWIST1 and GDF15 were up-regulated in cancer tissue, while CAV1 and PRKCA were down-regulated. More impressive was the diagnostic performance. When the four genes were combined into a single diagnostic model, the area under the receiver operating characteristic curve reached 0.990, a value approaching the theoretical maximum of 1.0 and indicating near-perfect discrimination between cancerous and non-cancerous samples. The authors emphasize that this four-gene signature could distinguish BaP-relevant molecular states in prostate tissue with a precision that single biomarkers rarely achieve, positioning the panel as both a mechanistic fingerprint of pollutant-driven carcinogenesis and a candidate clinical diagnostic tool.

Because tumors are not merely collections of malignant cells but complex ecosystems of immune, stromal, and epithelial populations, the team next examined how the core genes behave at single-cell resolution. Single-cell RNA sequencing data revealed the specific cellular distribution of each gene within the prostate tumor microenvironment and documented immunological shifts associated with their expression. Immune infiltration analysis at the bulk-tumor level reinforced the connection: the core genes were linked to cellular growth programs and to the recruitment of immune cells into tumors. This immunological dimension matters because previous research has suggested that BaP exposure can play an immunosuppressive role during prostate cancer progression, potentially helping tumors evade surveillance. The new findings place that immune remodeling on a firmer molecular footing, tying it to genes that are themselves responsive to BaP exposure.

To test whether the carcinogen could physically engage its putative targets, the researchers performed molecular docking, a computational technique that predicts how a small molecule fits into the binding pocket of a protein. The docking simulations showed that benzo[a]pyrene binds favorably to the core targets, providing a structural rationale for the associations uncovered by the network analysis. Docking results are inherently approximate and do not prove physiological binding in living cells, but within the study’s multi-layered design they serve as an important plausibility check, bridging the gap between statistical gene associations and the physical chemistry of pollutant-protein interactions.

Perhaps the most consequential portion of the work is its external validation. Computational pipelines in toxicology are sometimes criticized for generating elegant networks that evaporate under experimental scrutiny, so the authors tested their predictions with laboratory and dataset evidence outside the discovery pipeline. The validation confirmed that BaP may promote the progression of prostate cancer and reproduced the expected expression shifts: GDF15 up-regulated and PRKCA down-regulated in prostate cancer contexts linked to BaP exposure. The convergence of the computational prediction and the external evidence strengthens the causal narrative considerably, indicating that the four-gene axis is not an artifact of a single database or analytical choice but a reproducible molecular pattern.

The study arrives amid a growing wave of network toxicology applied to environmental carcinogens in urological cancers. Recent publications have used similar frameworks to implicate polycyclic aromatic hydrocarbons in reproductive health outcomes, to trace the oncogenic pathways of aristolochic acids across prostate, kidney, and bladder cancers, and to dissect the contributions of phthalates such as diethyl phthalate and DEHP to prostate carcinogenesis. Epidemiological work has also lent real-world weight to the hypothesis: occupational exposure to polycyclic aromatic hydrocarbons has been associated with elevated prostate cancer risk in case-control studies. What distinguishes the new paper is the breadth of its validation stack, extending from machine-learning biomarker selection through single-cell immunology to molecular docking and external experimental confirmation, all focused on a single Group 1 carcinogen that nearly every person encounters daily through diet, air, and tobacco smoke.

The implications cut in two directions. Clinically, a four-gene diagnostic panel with an AUC of 0.990 suggests that pollutant-driven molecular signatures could eventually complement prostate-specific antigen testing, which suffers from well-documented problems of overdiagnosis and poor specificity. If GDF15, for example, is already being explored as a circulating marker of response to docetaxel chemotherapy in metastatic castration-resistant prostate cancer, integrating exposure-linked gene panels into diagnostic algorithms could help identify which tumors are environmentally fueled and potentially which patients might benefit from interventions targeting the PI3K-Akt pathway, where several inhibitors are already under investigation in hormone-related cancers. Public health officials, meanwhile, may find in these results additional mechanistic justification for limiting BaP exposure through food preparation guidance, tobacco control, and air quality regulation, since the molecular evidence now traces a plausible route from charred protein and diesel soot to the transcriptional circuits of prostate tumors.

The authors are careful about scope. Their conclusions are framed as BaP potentially promoting prostate cancer development through regulation of CAV1, TWIST1, GDF15, and PRKCA, with causal certainty limited by the correlative nature of much of the transcriptomic evidence and by the approximate nature of docking predictions. The DU145 prostate cancer cell line used in their experiments is commercially available, and the study received support from the Guizhou Provincial Health Commission and related provincial research programs. Still, the work exemplifies a methodological shift that is transforming environmental oncology: instead of asking whether a chemical damages DNA, researchers now map the full network of its molecular conversations with human tissue, then test the strongest nodes experimentally. For a carcinogen as widespread as benzo[a]pyrene, and a cancer as prevalent as prostate cancer, that map may prove to be one of the most valuable public health documents of the decade.

Subject of Research: Molecular mechanisms linking benzo[a]pyrene exposure to prostate cancer

Article Title: Exploring the molecular mechanism of benzo[a]pyrene affecting prostate cancer based on network toxicology and external validation

Article References: Zhu, S., Li, Z., Jiang, K., Sun, F., & Zhu, J. (2026). Exploring the molecular mechanism of benzo[a]pyrene affecting prostate cancer based on network toxicology and external validation. Molecular Diversity. https://doi.org/10.1007/s11030-026-11729-6

Image Credits: AI Generated

DOI: 10.1007/s11030-026-11729-6

Keywords: benzo[a]pyrene, prostate cancer, network toxicology, machine learning, CAV1, TWIST1, PRKCA, GDF15, PI3K-Akt pathway, single-cell analysis, molecular docking, environmental carcinogens